Drug Profile


Alternative Names: GlycoPEG-GCSF; GlycoPEGylated G-CSF; GlycoPEGylated granulocyte colony-stimulating factor; Long-acting G-CSF - BioGeneriX/Teva; Long-acting Granulocyte Colony Stimulating Factor - BioGeneriX/Teva; Lonquex; XM-22

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioGeneriX; Neose Technologies
  • Developer BioGeneriX; Teva Pharmaceutical Industries
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 09 May 2016 Launched for Neutropenia (Chemotherapy-induced) in Israel (SC)
  • 02 Jun 2015 Merckel initiates enrolment in a phase IV trial for Neutropenia (Chemotherapy-induced) in Hungary (EudraCT2014-005096-85)
  • 01 May 2015 Merckle completes a phase I trial for Healthy volunteers in the UK (NCT02306915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top